Close

Press Releases

Atreca Raises $125 Million to Expand its Preclinical Pipeline and Advance its First Program into Clinical Trials

September 11, 2018

“REDWOOD  CITY,  Calif–  September  12,  2018  -­-­  Atreca,  Inc.,  a  biotechnology  company   focused  on  developing  novel  therapeutics  based  on  a  deep  understanding  of  the  human   immune  response,  announced  today  the  closing  of  an  oversubscribed  $125  million   financing.  This  Series  C  round  was  led  by  a  large  U.S.-­based,  healthcare-­focused  fund,   an  existing  Atreca  investor.  Participating  in  the  round  were  other  existing  investors   including  Wellington  Management  Company  LLC,  and  Cormorant  Asset  Management,   based  in  Boston,  and  joined  by  new  investors  Aisling  Capital,  Boxer  Capital  of  the   Tavistock  Group,  EcoR1  Capital,  Redmile  Group,  Samsara  BioCapital,  and  funds   managed  by  Tekla  Capital  Management.”

“This  funding  enables  us  to  broaden  and  accelerate  our  discovery  and  pipeline   generation  efforts  and  to  move  our  first  candidate  into  clinical  development,”  said  John   A.  Orwin,  President  and  Chief  Executive  Officer  of  Atreca.  “This  first  candidate,   generated  by  our  unique  Discovery  Engine  and  via  our  proprietary  Immune  Repertoire   Capture®  (IRC™)  technology,  represents  a  novel  and  potentially  fundamental  new  class   of  oncology  immunotherapeutics.    We  appreciate  the  support  of  both  our  new  and   existing  investors  as  we  advance  the  Company  to  this  next  stage  of  development.”

“Our  oversubscribed  Series  C  financing  provides  further  validation  of  Atreca’s  ability  to   discover  and  develop  high-­potential  therapeutic  candidates  via  its  unique  approach,”   said  Brian  Atwood,  Chairman  of  the  Board  of  Directors  of  Atreca.  “The  quality  of  the   investor  syndicate  and  magnitude  of  the  round  reflects  the  value  we  have  built  in  our   discovery  capabilities  and  the  progress  we  have  made  in  our  preclinical  programs  since   our  Series  B  financing  just  a  year  ago.”

Cowen  served  as  exclusive  placement  agent  for  the  financing.

About  Atreca,  Inc.
Atreca  is  a  privately  held  biotechnology  company  developing  novel  therapeutics  based   on  a  deep  understanding  of  the  human  immune  response.    We  focus  in  a  unique  way   on  the  immune  responses  of  patients  in  therapeutic  areas  where  such  responses  are  ”
the  key  phenomenon  driving  clinical  outcomes,  enabling  us  to  discover  and  develop   novel  immunotherapies.    Atreca  is  advancing  a  pipeline  of  candidates  designed  to  engage  the  human  immune  response  in  oncology  and  other  indications,  thus  driving   better  therapeutic  outcomes.  For  more  information  on  Atreca,  please  visit   www.atreca.com.

Contacts
Atreca,  Inc.
Susan  Berland
EVP  and  Chief  Financial  Officer   info@atreca.com
or
Media:
Nancie  Steinberg,  212-­213-­0006,  ext.  318
nsteinberg@burnsmc.com
Robert  Flamm,  212-­213-­0006,  ext.  364
rflamm@burnsmc.com
or
Investors:
John  Grimaldi,  212-­213-­0006,  ext.  362
jgrimaldi@burnsmc.com

Source:  Atreca,  Inc.